# Curriculum Vitae

# David Pearson, Ph.D.

**Associate Professor** 

Department of Pharmaceutical Sciences Ben and Maytee Fisch College of Pharmacy

The University of Texas at Tyler

Email: dpearson@uttyler.edu

## **Education:**

1989 Ph.D. Biochemistry, BioZentrum, University of Basel, Switzerland

Thesis Title: DNA sequences motifs required for hormonal regulation of the Urokinase Type Plasminogen Activator (uPA) gene.

Major Advisor: Dr. Professor Gottfried Schatz, Lab Supervisor: Dr. Yoshikuni Nagamine

Ph.D. degree Awarded Magna Cum Laude

1981 BS, Biochemistry, College of Agricultural & Environmental Science, UC Davis

## **Professional Experience:**

<u>06/2015 – Present;</u> Associate Professor with Tenure, Department of Pharmaceutical Sciences, Ben and Maytee Fisch College of Pharmacy, The University of Texas at Tyler, Texas

12/2013 – 05/2015; Interim Assistant VP-Research/ Head of the Office of Research at CNU

06/2013 - 02/2015; Assistant Dean for Research Affairs in the College of Pharmacy at CNU

<u>01/2015 – 05/2015</u>; Tenure-Track Associate Professor in the Department of Pharmaceutical and Biomedical Sciences, California Northstate University College of Pharmacy (CNUCOP), Elk Grove, Ca.

<u>02/2010 – 12/2014</u>; Tenure-Track Assistant Professor in the Department of Pharmaceutical and Biomedical Sciences, California Northstate University College of Pharmacy (CNUCOP), Elk Grove, Ca.

<u>08/2008 - 06/2010, 08/2011 - 12/2011</u>; Adjunct Lecturer, Department of Math and Science, Holy Names University (HNU), Oakland, Ca.

<u>06/2003 – 01/2008</u>; Research Chemist, Laboratory Manager of Dr. Joseph Tuscano, Flow Laboratory Manager, VA Mather Hospital, Ca.

<u>06/2003 – 06/2005</u>; Consultant, Department of Biomedical Engineering, Laboratory of Dr. Katherine Ferrara University of California, Davis, Development of Novel Targeted Micro-bubble Ultrasound Reagents

 $\underline{08/2002 - 06/2003}$ ; Post-Doc., Department of Biomedical Engineering, Laboratory of Dr. Katherine Ferrara. University of California, Davis, Ca.

<u>08/1999 – 08/2002</u>; Laboratory Manager PGR 10 / Post-Doc, Department of Biomedical Engineering, Laboratory of Dr. Scott Simon University of California, Davis, Ca.

<u>03/1996 – 06/1999</u>; Adjunct Assistant Professor, University of California at Davis, Medical School, Division of Trauma, Department. of Surgery, Sacramento, Ca.

01/1997 – 06/1999; Scientific Staff of The Shriners Hospital, Sacramento, Ca. Unit.

<u>09/1994 – 02/1996</u>; Adjunct Assistant Professor, Department of Biochemistry and Molecular Biology, College of Medicine, University of South Florida, Tampa, Fl.

<u>1989 – 1996</u>; Research Associate (Post Doc) at the Shriners Hospital for Crippled Children, Tampa Unit. Laboratory of Dr. J. Sasse, Immunology department, The regulation and expression of bFGF in cartilage

1983 – 1986; Postgraduate Fellowship at the Friedrich Miescher Institute, Basel, Switzerland

### **Honors and Awards:**

- 1. Ph.D. degree Awarded Magna Cum Laude
- 2. Received outstanding Post-Doc research award, Medical School, University of South Florida, 1994
- 3. 2013-2014 Inaugural AACP Academic Research Fellows Program recipient.

4. Leanne Coyne, Parto Khansari, Karen McClendon, <u>David Pearson</u>, Tiffanie Ho (2014) AACP Excellence in Assessment Award, AACP Annual Meeting, *Pharmacy Education 2014* in Grapevine, TX.

## **Instructional Experience:**

## **Courses Taught CNUCOP (Team Based Learning)**;

- 1. <u>Fall 2009, 2010, 2011</u>; Team teaching Cellular and Molecular Biology & Biochemistry PH621 (33% lectures, 20 contact hours) (topics include Bioinformatics, recombinant technology, viruses, gene expression, and regulation, genetics, Molecular targets).
- 2. <u>Fall 2010 (72.5 contact hours), 2011, 2012, 2013 (58 contact hours)</u>; Developer, Course Coordinator and Instructor (2014) for Clinical Immunology and Rheumatology PHAR 827
- 3. <u>Spring 2011</u>; Team Teaching Biotechnology and Pharmacogenomics PHAR 826 (27% lectures, 12 contact hours). (topics taught; review of molecular biology and human genomics, genetic testing and bioinformatics, recombinant technology and biopharmaceutics, gene therapy and stem cell therapy)
- 4. Spring 2012, 2013; Course Coordinator and Instructor for Biotechnology and Pharmacogenomics PHAR 826 (53% lectures, 24 contact hours). (review of molecular biology and human genomics, genetic testing and bioinformatics, recombinant technology and biopharmaceutics, gene therapy and stem cell therapy, ethical, legal and regulatory issues, medical imaging technology)
- 5. <u>Fall 2011</u>; Team Teaching Therapeutics PHAR853 (topics taught; cancer genomics, multidrug resistance, cancer markers biology and lab markers, hematology, growth factors and BM/stem cell transplantation sections) (9 contact hours)
- 6. Fall 2011, 2012, 2014: Grading P1 students in their SOAP presentations.

#### **Electives Taught at CNUCOP**;

- 1. <u>Spring 2013, 2014, 2015</u>: Co-Coordinator; Bioassay-Guided Isolation and Characterization of Natural Products (PHAR 781F/881F) 2 units
- 2. Spring 2014,: Departmental Elective Topic Bioterrorism and the Role of the Pharmacist
- 3. Spring 2015; Nutrition elective for pharmacist
- 4. Spring 2015; Independent Study Research Elective

#### **HNU** (Traditional Lecture);

- 1. 2009-2010; Course Coordinator; Chemistry 7 lab Nursing program
- 2. 2009-2010; Course Coordinator; Nutrition 1
- 3. 2008-2009; Course Coordinator; Biology 1a Laboratory Nursing program
- 4. 2009; Course Coordinator Biochemistry 170 / Immunology 130 laboratory course
- 5. 2009, 2011; Course Coordinator; Human Biology 15 General Ed.

Other past formal courses taught; Medical Biochemistry (team taught; University of South Florida), Immunology, Molecular and Cellular Biology and Graduate Immunology Seminar class (UC Davis). Everyday laboratory teaching to undergraduate, graduate students and surgical residents bench biochemistry, immunology, molecular biology, tissue culture, cloning, bioinformatics etc. on an individual student basis.

#### **Academic Service:**

- 2006 2008; Ad-hoc outside reviewer for the Advisory Research Committee's Pilot Idea Award Grants at UC Davis School of Medicine
- 2. 05/2011 Present; Reviewer for Inflammopharmacology Springer journal
- 3. 07/2011 Present; Editor for the International Journal of Pharmacy
- 4. <u>11/2012 Present</u>; Reviewer for Clinical Pharmacology and Biopharmaceutics
- 5. <u>11/2012 Present;</u> Invited to join Editorial board for Journal of Pharmacovigilance
- 6. 05/2013 Present; Reviewer for MedEdPortal, Association of American Medical College
- 7. 08/2013 Present; Reviewer for AACP New Investigator Awards grants

- 8. 05/2014 Present; Abstract Reviewer for AAMC Medical Education Meetings, 2014, 2015 9. 09/2014 - Present; AACP Administrative Services Section: Strategic Planning Committee
- 10. <u>04/2015 Present:</u> Abstract Reviewer for AACP 2015 Meeting
- 11. 04/2015 Present: Abstract Reviewer for ABCD 2015 Meeting, Santa Fe, NM
- 12. 05/04/2015 Co-Chair of Biochemistry in Pharmacy Break out Session B

## **Associations and Memberships:**

- Association of Biochemistry Course Directors (ABCD) 1. 08/2010 - Present; Elected Executive Board Member since 05/2013
- 2. 04/2011 05/2015; UC Davis Cancer Center
- 3. 11/2011– Present; American Association of Colleges of Pharmacy (AACP)
- 4. 10/2012 Present; American Society for Cell Biology (ASCB)
- Named to the Sacramento Metro Chamber of Commerce Healthcare and 5. 04/2013 - Present; **Biosciences Committee**

# **Committee Service @ UT Tyler;**

- 1. <u>06/2015 Present</u>; College of Pharmacy Assessment Committee
- 2. <u>06/2015 Present</u>; College of Pharmacy Admissions Committee
- 3. 07/2015 Present; University IRB Member

# **Committee Service @ CNUCOP:**

- 6. 03/2010 08/2013; Assessment Committee (Co-Chair 03/2010-07/2012)
- 7. 07/2010 07/2012; Safety Committee and Safety Coordinator for Research Lab facility for the college
- 8. 07/2010 08/2013, 08/2014 05/2015; Professional and Academic Standards Committee (PASC),
  - Appointed Chair (07/2011-08/2013)
- 9. 07/2010 08/2011; Milestone Committee
- 10. 01/2011 06/2013; **Chair** of Faculty Council, (founding member and by-laws development)
  - Elected Chair (05/2012)
- 11. 04/2011 05/2015; IRB Committee (founding member and development)
- 12. 05/2012 02/2015; President's Executive Council, voting member
- 13. 05/2012 02/2015; Dean's Executive Committee, voting member
- 14. 07/2012 02/2015; Bylaws and Policy Development Committee **founding member**
- 15. 08/2012 05/2015Chair Physical Space Committee, Appointed Chair (1/2014)
- $16. \ 02/2013 05/2015$ ; COP Research Committee ex officio
- 17. 08/2013 02/2015; Seed Grant Committee ex officio
- $18. \ 08/2013 07/2014;$ Tenure and Promotion Committee **Junior Faculty Representative**
- 19. 08/2013 02/2015; **Chair** of the Exploratory TBL Center Committee
- $20.\ 08/2014 05/2015$ ; Honor Board

# Ad-Hoc Committee @ CNUCOP:

- 1. 05/2010 07/2010; WASC Standards 1
- 2. 05/2011 02/2012; Advisory Search for the new Dean of Pharmacy position (DASC)
- 3. 08/2011 09/2011; SWOT self-study
- 4. 08/2011 03/2012; Promotion and Tenure Criteria development
- 5. 09/2011 02/2012; Self-study for ACPE Standards 24-26 for Accreditation
- 6. 08/2012 02/2013; Chair of the search committee to fill the Associate Dean for Academic Affairs position in the College of Pharmacy.
- 7. 07/2012 11/2012; Strategic Planning for the College of Pharmacy 5 year plan

- 8. <u>09/2013 05/2015</u>; <u>Chair</u> of search committee to fill Cardiovascular-Pharmacology faculty position in PharmSci Department
- 9. <u>09/2013 08/2014, 01/2015 05/2015:</u> Member of the search committee to fill the Pharmacokinetics faculty position in PharmSci Department
- 10. 10/2013 08/2014; College of Pharmacy Enrollment Initiative Committee
- 11. <u>12/2013 04/2014</u>; <u>Chair</u> of search committee for the new Dean of the Undergraduate Health Sciences Program at CNU
- 12. 08/2013 02/2015: Strategic Planning Financial Stability Committee
- 13. <u>08/2013 02/2015:</u> Strategic Planning Department Committee
- 14. <u>08/2013 02/2015:</u> Strategic Planning Research Committee

### Task Force @ CNUCOP:

1. <u>08/2011- 02/2013</u>; Self Study college satisfaction survey results to make improvements to college.

## **Committees @ CNU University Level:**

- 1. <u>10/2012 06/2013:</u> <u>Co-Chair</u>, Faculty Senate, (By-laws development)
- 2. 03/2013 02/2015; Chair, University Research Council
- 3.  $\overline{12/2013 05/2015}$ ; Biosafety Committee *ex officio*
- 4. <u>12/2013 05/2015</u>; Safety Committee *ex officio*
- 5. <u>12/2013 05/2015</u>; Institutional Animal Care and Use Committee (IACUCC) *ex officio*
- **6.** <u>12/2013 05/2015</u>; Institutional Review Board (**IRB**) *ex officio*
- 7. 12/2013 05/2015; Radiation Safety Committee ex officio

## **Faculty Advisor to Clubs at CNUCOP:**

- 1. 02/2011 05/2015; Christian Pharmacists Fellowship International
- 2. <u>11/2011 09/2013</u>; Pharmacy Frontiers Club
- 3. <u>2/2014 2/2015</u>; CAPSLED Research Project

### **APPE Student Rotation at CNUCOP:**

- 1. Steven Iannone; April 1, 2012- May 11, 2012 (Academic)
- 2. Priyank Shah; February 15, 2013 March 31, 2013 (Academic/Research)
- 3. Loc Duc Ngo; May 15, 2014 June 28, 2014 (Academic)
- 4. Seveen Alexander; June 30, 2014 August 17, 2014 (Academic)
- 5. Yen Nguyen; August 18, 2015 September 9, 2014 (Academic)

#### **IPPE Student Rotation at CNUCOP:**

- 1. Tagui Arabyan January 7, 2013 April 29, 2013 (Laboratory/Academic)
- 2. Phoebe Dinh January 7, 2013 April 29, 2013 (Laboratory/Academic)
- 3. Randall Husk January 7, 2013 April 29, 2013 (Laboratory/Academic)
- 4. Van Voong January 7, 2013 April 29, 2013 (Laboratory/Academic)

#### **Publications:**

- **1.** Nagamine, Y., <u>Pearson, D</u>., Altus, M. S. and Reich, E. (1984) The cDNA and gene nucleotide sequence of porcine plasminogen activator. *Nucl. Acids Res.* **12**:9525-9541
- **2.** Nagamine, Y., **Pearson, D**., and Grattan, M. (1985) Exon-intron boundary sliding in the generation of two mRNAs coding for porcine urokinase-like plasminogen activator. *Biochem. Biophy. Res. Commun.* **132:** 563-569

- **3.** Altus, M. S., <u>Pearson, D</u>., Horiuchi, A. and Nagamine, Y. (1987) Inhibition of protein synthesis in LLC-PK1 cells increases calcitonin-induced plasminogen activator gene transcription and mRNA stability. *Biochem. J.* **242:**387-392
- **4.** <u>Pearson, D.</u>, Altus, M. S., Horiuchi, A. and Nagamine, Y. (1987) Dexamethasone coordinately inhibits plasminogen activator gene expression and enzyme activity in porcine kidney cells. *Biochem. Biophy. Res. Commun.* **143:**329-336
- **5.** Hofstetter, P., Kikinis, Z., Altus, M. S., <u>Pearson, D</u>. and Nagamine, Y. (1987) A new genetic approach for studing hormonal regulation of urokinase-type plasminogen activator gene expression in LLC-PK1. *Mol. Cell. Biol.* **7:** 4535-4541
- **6.** Nakagawa, J., von der Ahe, D., <u>Pearson, D</u>., Hemmings, B. A., Shibahara, S. and Nagamine, Y. (1988) Transcriptional regulation of a plasminogen activator gene by cyclic AMP in a homologous cell-free system. *J. Biol. Chem.* **263:**2460-2468
- 7. Andrus, L., Altus, M. S., <u>Pearson, D.</u> and Nagamine, Y. (1988) Hsp70 mRNA accumulates in LLC-PK1 pig kidney cells treated with calcitonin but not with 8-bromo-cyclic AMP. *J. Biol. Chem.* **263:**6183-6187
- **8.** von der Ahe, D., <u>Pearson, D.</u>, Nakagawa, J., Rajput, B. and Nagamine, Y. (1988) Multiple nuclear factors interact with promoter sequences of the urokinase-type plasminogen activator gene. *Nucl. Acids Res.* **16**:7527-7982
- **9.** Pearson, C. A., <u>Pearson, D.</u>, Shibahara, S., Hofsteenge, J., and Chiquet-Ehrismann, R. (1988) Tenascin: cDNA cloning and induction by TGF-Beta. *EMBO* **7:**2977-2982
- **10**. von der Ahe, D., <u>Pearson, D</u>. and Nagamine, Y. (1990) Macromolecular interaction on a cAMP responsive region in the urokinase-type plasminogen activator gene: a role of protein-p hosphorylation. *Nucl. Acids Res.* **18**:1991-1999
- **11.** <u>Pearson, D.</u>, Niggs, E. A., Nagamine, Y., Jans, D. A., and Hemmings, B. A. (1991) Mechanisms of cAMP-mediated gene induction: examination of renal epithelial cell mutations affected in the catalytic subunit of the cAMP-dependent protein kinase. *Exp. Cell Res.* **192:**315-318
- **12.** Cassady, A. I., Stacey, K. J., Nimmo, K. A., Murphy, K. M., von der Ahe, D., <u>Pearson, D.</u>, Botteri, F. M., Nagamine, Y., Hume, D. A. (1991) Constitutive expression of the urokinase plasminogen activator gene in murine RAW264 macrophages involves distal and 5' non-coding sequences that are conserved between mouse and pig. *Nucl. Acids Res.* **19:**6939-6847
- **13.** <u>Pearson, D</u>. and Sasse, J. (1992) Differential regulation of biglycan and decorin mRNAs by retinoic acid in articular chondrocytes. *J. Biol. Chem.* **267**:25364-25370.
- **14.** Sasse, J., <u>Pearson, D.</u>, and Smale, G. (1993). Regulation of basic fibroblast growth factor expression in cartilage: simultaneous expression of basic FGF and of a natural antisense FGF transcript in articular cartilage. *J. Cellular Biochemistry* **17E:**163.
- **15.** Barry, F. P., Sasse, J., Neame, P. J., and <u>Pearson, D</u>. (1994) Length variation in the keratan sulfate domain of mammalian aggrecan. *Matrix Biology* **14**:323-328
- **16.** Sasse, J., Coffin. D., Govindraj, P., <u>Pearson, D</u>., and Ganey, T. (1994) Over expression of FGF-2 (basic fibroblast growth factor) in transgenic mice: alteration of skeletal development. *Mol. Biol. of the Cell* **5**:466a
- **17.** Bush, R. L., Pevec, W. C., Ndoye, A., Cheung, A. T. W., Sasse, J., and **Pearson, D.** (1998) Regulation of new blood vessel growth into ischemic skeletal muscle. *J. Vascular Surg.* **28**:919-928
- **18.** Koolpe, M., <u>Pearson, D</u>., and Benton, H. P. (1998) Expression of both P1 and P2 purine receptors by human articular chondrocytes and Profile of Ligand-Mediated Prostaglandin E2 Release. *Arthritis and Rheumatism* **42**:258-267
- **19.** Smolen, J. E., Petersen, T. K., Koch, C., O'Keefe, S. J., Hanlon, W. A., Seo, S., <u>Pearson, D</u>, Fossett M. C., Simon, S. I. (2000) L-selectin signaling of neutrophil adhesion and degranulation involves p38 mitogen-activated protein kinase. *J Biol Chem* **275**:15876-84
- **20.** Rodriquez, V., Grove, J., Yelich, S., <u>Pearson, D</u>., Stein, M., and Pevec, W., (2002) Effects of bradchytherapy on intimal hyperplasia in arteriovenous fistulae in pigs. *J Vasc Interv Radiol*. **12**:1239-46.
- **21.** Green, C. E., <u>Pearson</u>, <u>D</u>., and S. I. Simon (2002) Valency requirements for selectin mediated signaling and receptor colocalization on neutrophils. *Mol. Biol. of the Cell.* **13**:398a
- 22. <u>Pearson, D.,</u> C. E. Green, and S. I. Simon (2002) E-Selectin signals rapid activation of neutrophils through L-selectin and PSGL-1. *Mol. Biol. of the Cell.* 13:399a

- **23.** Green, C.E., <u>Pearson, D.</u>, Christiansen, N., and Simon, S. I., (2002) Topographic requirements and dynamics of signaling via L-selectin on neutrophils. *J. of Cell Physiology* **284**:205-217
- **24.** Dayton, P.A., <u>Pearson, D.</u>, Clark, J., Simon, S., Schumann, P.A., Zutshi, R., Matsunaga, T.O., Ferrara, K.W.(2004) Ultrasonic analysis of peptide- and antibody-targeted microbubble contrast agents for molecular imaging of  $\alpha_v \beta_3$ -expressing cells. *Mol Imaging*. 3(2):125-34.
- **25.** Green, C.E., <u>Pearson, D.N.</u>, Camphausen, R.T., Staunton, D.E., Simon, S.I. (2004) Shear-dependent capping of L-selectin and P-selectin glycoprotein ligand 1 by E-selectin signals activation of high-avidity beta2-integrin on neutrophils. *J Immunol.* 172(12):7780-90.
- **26.** <u>David Pearson</u>, Miguel Cerejo, Hayes C. McKnight, Xiaobing Wang, Jan Mařik, Robert T. O'Donnell, Thomas F. Tedder, Kit Lam and Joseph Tuscano. (2008) CD22-binding Peptides Derived from Highly Conserved Anti-CD22 Ligand Blocking Antibodies Targeted Lymphoma Cell Death by Novel Signal Transduction Modifications. *Int. J. of Pept. Res. Ther.* 14:237-246
- **27.** O'Donnell, R.T., <u>Pearson, D.</u>, McKnight, H., Tedder, T.F., and Tuscano, J. M. (2009) Phosphatase Inhibition Augments Anti-CD22-Mediated Signaling and Cytotoxicity in Non-Hodgkin's Lymphoma Cells. Leukemia Research. *Leuk Res.* Jul;33(7):964-969.
- **28.** O'Donnell, R.T., <u>Pearson, D.</u>, McKnight, H. C., Ma, Y. P., and Tuscano, J. M. (2009) Treatment of non-Hodgkin's Lymphoma Xenografts with the HB22.7 anti-CD22 Monoclonal Antibody and Phosphatase Inhibitors Improve Efficacy. *Cancer Immunol Immunother*. Oct;58(10):1715-1722
- **29.** O'Donnell, R.T., Ma, Y. P, McKnight, H. C., <u>Pearson, D</u>. and Tuscano, J. M. (2009) Dose, Timing, Schedule, and the Choice of Targeted Epitope Alter the Efficacy of Anti-CD22 Immunotherapy in Mice Bearing Human Lymphoma Xenographs. *Cancer Immunol Immunother*. Dec; 58(12):2051-2058
- **30.** (**Invited Review, Peer Reviewed**); Xiaodong Feng, Brad Brazil, and **David Pearson** (2011) Therapeutic Application of Pharmacogenomics in Oncology: Selective Biomarkers for Cancer Treatment. *US Pharmacist* 2011;36(11)(Oncology suppl):5-12 <a href="http://www.uspharmacist.com/content/s/190/c/31076/">http://www.uspharmacist.com/content/s/190/c/31076/</a>
- **31**. (**Invited Review, Peer Reviewed**); Xiaodong Feng <u>David Pearson</u>, Mario Listiawan, and Cindy Cheung (2012) Therapeutic Application of Pharmacogenomics in Oncology: Biomarkers for Toxicities Associated with Cancer Treatment *US Pharm*. 2012;37(1)(Oncology suppl):2-
- 7. http://www.uspharmacist.com/content/s/194/c/32004/
- **32.** Tibebe Z. Woldemariam, Nancy Wageih Hanna and <u>David Pearson</u> (2012) Pharmacogenetics: Would it be a reason for the lack of potency and intrinsic toxicity of several natural medicines. J. Proteomics Bioinform, 5:6.-83 <a href="http://dx.doi.org/10.4172/0974-276x.s1.064">http://dx.doi.org/10.4172/0974-276x.s1.064</a>
- **33.** Joseph M. Tuscano, Jason Kato, **David Pearson**, Chengyi Xiong, Laura Newell, Yunpeng Ma, David R. Gandara and Robert T. O'Donnell (2012) The CD22 B-Cell Antigen is Broadly Expressed on Lung Cancer Cells and is a Target for Antibody-based Therapy. *Cancer Research* November 1, 72 (21)5556-5565
- **34.** Tibebe Z. Woldemariam, Anahita Malekakhlagh, Caroline Bett, and **David Pearson** (2014) Evaluation of the Anti-Tumor Activity of Selected Herbs and Spices. J. Pharm. Sci. Pharmacol. 1, 296-303
- **35.** Neil Osheroff, Eric Niederhoffer, Richard L. Sabina, Susan D. Cline, Mary J. Wimmer, David S. Franklin, Alan, B. Diekman, Tanis Hogg, Kevin R. Kearney, Steven, C. King, **David Pearson**, Clive A. Slaughter, and Kathryn Thompson (2015) Teaching Biochemistry to Students of Medicine, Pharmacy & Dentistry. Medical Science Educator (*in press*)
- **36.** David Lopez, Kristina Pedersen, Doan Trang Duong, Tatevik Kirakosyan, Rebecca Lemus, Omi Patel, Laura Smith, Stefanie Stafford, Cyndi Porter, and **David Pearson** (2015) Pharmacy School Interprofessional Education Models An Evaluative Comparison for the Future of Pharmacy Practice in California (*submitted*)
- **37**. Tibebe Z. Woldemariam, Dan Pham, Yun H. Kim, Kathy Phan, Linh Puoy, Kieu T. Nguyen, Joseph M. Tuscano and **David Pearson** (2015) Evaluation of the anti-tumor activity of selected herbs and spices. (*manuscript in preparation*)

# **Book Chapters:**

- **1.** Nagamine, Y., Altus, M. S., Nakagawa, J., <u>Pearson, D</u>., von der Ahe, D., Urokinase-type plasminogen activator gene regulation as a model system for studying transcriptional activation by the cAMP-dependent protein kinase pathway. In: Hormonal control of gene transcription. (ed. Cohen, P.), Elsevier Scientific Publishers, Amsterdam, 1991.
- **2.** Stacey, K. J., Cassady, A. I., Nimmo, K. A., Murphy, K. M., von der Ahe, D., **Pearson, D**., Botteri, F. M., Nagamine, Y., Hume, D. A. (1992) The regulation of urokinase plasminogen activator gene expression in macrophages, In: van Furth R (ed) Mononuclear phagocyes. Kluwer Academic Publishers, Dordrecht, Netherlands, pp233-240

## **Abstracts / Posters and Presentations:**

- **1.** <u>Pearson, D.</u>, von der Ahe, and Y. Nagamine (1988) DNA sequences involved in the hormonal regulation of the uPA gene. 20th Annual Meeting of the Union of the Swiss Societies for Experimental Biology, Interlaken.
- **2.** Pearson, C. A., Shibahara, S., <u>Pearson, D</u>., and R. Chiquet-Ehrismann. (1988) Molecular cloning of the extracellular matrix protein tenascin reveals heterogeneity at the 3' ends of the cDNAs. 20th Annual Meeting of the Union of the Swiss Societies for Experimental Biology, Interlaken.
- **3.** <u>Pearson, D</u>, von der Ahe, D., and Nagamine, Y. Macromolecular interaction on a cAMP responsive region in the urokinase-type plasminogen activator gene. (1989) Gordon Conference "Hormonal Regulation and Protein Phosphorylation".
- **4.** <u>Pearson, D</u>. and Sasse, J. (1991) Differential regulation of DSPG's by retinoic acid in bovine articular chondrocytes. 21st Southern Connective Tissue Society Meeting, Tampa, Fl.
- **5.** Smale, G., Govindraj, P., <u>Pearson, D.</u>, and Sasse, J. (1991). Basic FGF expression in cartilage: expression of bFGF message and a natural antisense bFGF transcript. 22nd Southern Connective Tissue Society Meeting, Chapel Hill. SC.
- **6.** <u>Pearson, D</u>. and Sasse, J. (1991) Differential regulation of biglycan and decorin by retinoic acid in bovine articular chondrocytes. Gordon Conference "The molecular Biology of Bone and Teeth.
- **7.** <u>Pearson, D.</u> and Sasse, J. (1992) Differential regulation of biglycan and decorin by retinoic acid in bovine articular chondrocytes. J. Bone and Joint Surgery
- **8.** <u>Pearson, D</u>. and Sasse, J. (1992) Differential regulation of biglycan and decorin by retinoic acid in bovine articular chondrocytes. Orthopedic Research Society Meeting, Washington D.C.
- **9.** Sasse, J., <u>Pearson, D</u>., Govindraj, P., and Smale, G. (1993) Regulation of basic fibroblast growth factor expression in cartilage: simultaneous expression of basic FGF and of a natural antisense FGF transcript in articular cartilage. American Society for Bone and Mineral Research, Tampa, Fl.
- **10.** Ganey, T. M., <u>Pearson, D</u>., Klotch, D. W., O'Neal, M. L., Sasse, J., Ogden, J. A. (1993) Genetic expression of decorin and biglycan during distraction osteogenesis. Health Science Center, University of South Florida, Research Day, Tampa, FL.
- **11.** <u>Pearson, D.</u>, Sasse, J., Neame, P. J., and Barry, F. P. (1993) Length variation in the aggrecan keratan sulfate domain investigated by PCR. Health Science Center, University of South Florida, Research Day, Tampa, FL.
- **12.** <u>Pearson, D.</u> and Sasse, J. (1993) Sense and antisense transcripts of basic fibroblast growth factor are expressed and regulated separately in embryonic and adult tissues. Gordon Conference "The molecular Biology of Bone and Teeth".
- **13.** <u>Pearson, D</u>. and Sasse, J. (1994) Sense and antisense transcripts of basic fibroblast growth factor are expressed and regulated separately in embryonic and adult tissues. Orthopedic Research Society Meeting, New Orleans, LA.
- **14**. Ganey, T. M., <u>Pearson, D</u>., Klotch, D. W., Sasse, J. (1994) Genetic expression of decorin and biglycan during distraction osteogenesis. Orthopedic Research Society Meeting, New Orleans, LA.
- **15.** Barry, F. P., Sasse, J., Neame, P. J., and <u>Pearson, D.</u> (1994) Analysis of the keratan sulfate domain of human, porcine and canine aggrecan using PCR. Orthopedic Research Society Meeting, New Orleans, LA.

- **16.** <u>Pearson, D</u>. and Sasse, J. (1994) Antisense transcripts of FGF-2 are expressed and regulated separately in embryonic and adult tissues. 14th Annual Florida Biochemist Meeting, Clearwater, FL.
- 17. <u>Pearson, D.</u>, Ganey, T. M., and Sasse, J. (1994) Sense and antisense transcripts of basic fibroblast growth factor are expressed and regulated separately in embryonic and adult tissues. Gordon Conference "Peptide Growth Factors".
- **18.** Ganey, T., Coffin, D., Govindraj, P., <u>Pearson, D</u>., and Sasse, J. (1995) Disturbance of cartilage and bone development in transgenic mice over expressing FGF-2 (basic fibroblast growth factor). Orthopedic Research Society Meeting, Orlando, Fl.
- **19.** Sasse, J., Coffin, D., <u>Pearson, D</u>., Govindraj, P., and Ganey, T. (1995) Over expression of the angiogenic fibroblast growth factor FGF-2 in transgenic mice causes alteration of skeletal development. American Cancer Society Meeting, Orlando, FL.
- **20.** <u>Pearson, D.</u>, Ganey, T. M., and Sasse, J. (1995) Antisense transcripts of FGF-2 are expressed and regulated separately from sense FGF-2 transcripts in embryonic and adult tissues. American Cancer Society Meeting, Orlando, FL.
- **21.** Sasse, J., Coffin, D., <u>Pearson, D</u>., Govindraj, P., and Ganey, T. (1995) Over expression of FGF-2 (basic fibroblast growth factor) in transgenic mice causes alteration of skeletal development. FASEB Meeting, Atlanta, GA.
- **22.** <u>Pearson, D</u>. (1996) Regulation of FGF-2 Expression by Endogenous Antisense RNA. UC Davis Cancer Center Research Symposium Sacramento, CA.
- **23.** Bush, R. L., Pevec, W.C., Nydoye, A., Cheung, A. T. W., Sasse, J., and <u>Pearson, D</u>. (1997) Regulation of new blood vessel growth into ischemic tissue. Eight Annual Surgical Resident Research Day. UCDMC, Sacramento, CA.
- **24**. Bush, R. L., Pevec, W.C., Nydoye, A., Cheung, A. T. W., Sasse, J., and <u>Pearson, D</u>. (1997) Regulation of new blood vessel growth into ischemic skeletal muscle. 105th Western Surgical Association Scientific Meeting, Colorado Springs, CO.
- **25**. Petersen, D. and <u>Pearson, D</u>. (1997) T lymphocyte secretion of FGF-2 in relation to angiogenesis; 18, 21, 23 KDa FGF-2 protein and antisense mRNA transcript of FGF-2 gene. West Coast Undergraduate Biological Sciences, San Diego, CA.
- **26.** Koolpe, M., <u>Pearson, D.</u>, and Benton, H.P. (1998) Interleukin 1 (IL-1) induced modulation of adenosine receptor expression in human rheumatoid synovial cells. ASCB
- **27.** Aragones, N., MacCall, K., Battistella, F. and <u>Pearson, D.</u> (1998) Cytokine expression in the immune system following trauma. National Minority Research Symposium, San Diego, CA.
- **28.** <u>Pearson, D.</u> Young, L.J.T., and Greenhalgh, D.G. (1999) Analysis of cell types in the lung following large area thermal injury using flow cytometry. Keystone Meeting on Immunological and Biological Aspects of Therapeutic Protein Delivery to the Lungs.
- **29.** Simon, S. I., O'Keefe, S. J., Fossett, M. C., <u>Pearson, D</u>, and Smolen, J. E. (2000) L-Selectin signaling of neutrophil function involves P38 MAP kinase. FASEB Meeting, San Diego, CA.
- **30.** Simon, S. I. and **Pearson, D.** (2000) Topographic requirements for signaling neutrophil activation through L-selectin. 2000 Annual Fall Meeting of the Biomedical Engineering Society, Seattle, WA.
- **31.** Simon, S. I. and <u>Pearson, D.</u> (2001) From cell rolling to arrest: Topographic requirements of signaling via L-selectin. 2001 Annual Meeting of the Biomedical Engineering Society, Park City, UT.
- **32.** Simon, S. I., Green, C. E. and <u>Pearson, D.</u> (2002) From cell rolling to arrest: Topographic requirements of signaling via L-selectin and PSGL-1. Keystone Meeting on Inflammation, Steamboat Springs, CO.
- **33**. Green, C. E., <u>Pearson, D</u>., Simon, S. I. (2002) Valency requirements for selectin mediated signaling and receptor colocalization on neutrophils. 43<sup>rd</sup> Annual Cell Biology Meeting, San Francisco, CA
- **34.** <u>Pearson, D</u>., Green, C. E., and Simon, S. I. (2002) E-Selectin signals rapid activation of neutrophils through L-selectin and PSGL-1. 43<sup>rd</sup> Annual Cell Biology Meeting, San Francisco, CA.
- **35.** Dayton, P., <u>Pearson, D</u>., Clark, J., Simon, S., Schumann, P., Zutshi, R., Matsunaga, T., and Ferrara, K. (2003) Ultrasonic enhancement of  $\alpha_{\nu}\beta_{3}$ -expressing cells with targeted contrast agents. IEEE Meeting, Honolulu, Hawaii

- **36.** Dayton, P., <u>Pearson, D</u>., Clark, J., Simon, S., Schumann, P., Zutshi, R., Matsunaga, T., and Ferrara, K. (2003) Enhanced ultrasonic detection of  $\alpha_v \beta_3$  expressing-cells with targeted contrast agents. Molecular Imaging Conference, San Francisco, CA. (Poster)
- **37.** O'Donnell, R.T., <u>Pearson, D.</u>, McKnight, H., Tedder, T.F., and Tuscano, J. M. (2006) Sodium orthovanadate (NaV) effects CD22 expression, intracellular signaling, and lymphomacidal activity of the HB22.7 anti-CD22 monoclonal antibody. American Society of Hematology Meeting, Atlanta, GA. (Poster)
- **38.** O'Donnell, R.T., <u>Pearson, D.</u>, McKnight, H., Tedder, T.F., and Tuscano, J. M. (2007) The Cd22 Epitope, dose, dosing interval, and timing all effect efficacy of anti-CD22 mAb- based therapy of NHL. American Society of Hematology Meeting, Atlanta, GA. (Poster)
- **39.** Tibebe Z. Woldemariam, Dan Pham, Yun H. Kim, Kathy Phan, Linh Puoy, Kieu T. Nguyen, Joseph M. Tuscano and **David Pearson** (2011) Evaluation of the anti-tumour activity of selected herbs and spices. 52<sup>nd</sup> Annual Meeting of the American Society of Pharmacognosy Meeting, San Diego, CA.(Poster)
- **40. David Pearson,** Joseph M. Tuscano and Tibebe Z. Woldemariam (2012) Evaluation of Anti-tumor Activity Isolated From Selected Herbs And Spices. ASCB Meeting, San Francisco, CA.(Poster)
- **41.** <u>David Pearson</u>, L. J. Brunner, and T.Z. Woldemariam (2013) The use of Team-Based Learning (TBL) in an elective research laboratory course in a PharmD curriculum. 4<sup>th</sup> International ABCD Conference, Santa Fe, NM.(Poster)
- **42.** <u>David Pearson</u>, X. Feng and R. Vinall (2013) The Ins and Outs of Team-Based Learning (TBL) pedagogy in teaching cellular and molecular biology /biochemistry in a doctor of Pharmacy program. (<u>90 minute workshop</u>) 4<sup>th</sup> International ABCD Conference, Santa Fe, NM. (Invited)
- **43.** Tibebe Z. Woldemariam, Sara Eun Choi, Carrie Dean, Zahra Tabib, **David Pearson.** (2013) Evaluation of Cytotoxic Activity of Rosemarinic Acid. 52nd Annual Meeting of the Phytochemical Society of North America (Poster)
- **44.** Ruth Vinall; Moon Chen; Julie Dang, Xiaodong Feng, Cyndi Porter, Dai Nguyen, James A. Palmieri, **David Pearson** (2014) Collaboration between pharmacy students and an NCI-designated Comprehensive Cancer Center to address cancer health disparities. AACP Annual Meeting, *Pharmacy Education 2014* in Grapevine, TX. (Poster)
- **45.** Leanne Coyne, Parto Khansari, Karen McClendon, <u>David Pearson</u>, Tiffanie Ho (2014) AACP Excellence in Assessment Award, AACP Annual Meeting, *Pharmacy Education 2014* in Grapevine, TX. (Presentation)
- **46.** <u>David Pearson</u> (2014) <u>Research Mentoring Program at CNUCOP Research Fellow Project/Poster.</u> AACP Annual Meeting, *Pharmacy Education 2014* in Grapevine, TX.
- **47.** Tibebe Z. Woldemariam, Sara Eun Choi, Carrie Dean, Zahra Tabib, **David Pearson** (2014) Evaluation of Anti-Tumour Activity of Rosemarinic Acid. Student National Pharmaceutical Association (SnPhA) annual meeting, Arlington, VA (Poster)
- **48.** David Lopez, Kristina Pedersen, Doan Trang Duong, Tatevik Kirakosyan, Rebecca Lemus, Omi Patel, Laura Smith, Stefanie Stafford, **David Pearson**, Cyndi Porter (2014) Pharmacy School Interprofessional Education Models- An Evaluative Comparison for the Future of Pharmacy Practice in California, CAPSLEAD CSHP San Francisco, CA (Poster)
- **49.** David Lopez, Kristina Pedersen, Doan Trang Duong, Tatevik Kirakosyan, Rebecca Lemus, Omi Patel, Laura Smith, Stefanie Stafford, **David Pearson**, Cyndi Porter (2014) Pharmacy School Interprofessional Education Models- An Evaluative Comparison for the Future of Pharmacy Practice in California, CAPSLEAD the Midyear Summer Meeting 2015 ASHP, Denver, CO.(Poster)
- **50.** <u>David Pearson</u> and Tibebe Woldemariam (2015) The Use of TBL in a Non-Traditional Laboratory Elective Course, A 3 Year Perspective. ABCD Meeting, Santa Fe, NM (Invited Presentation)
- **51.** David Lopez, Kristina Pedersen, Doan Trang Duong, Tatevik Kirakosyan, Rebecca Lemus, Omi Patel, Laura Smith, Stefanie Stafford, **David Pearson**, Cyndi Porter (2014) Pharmacy School Interprofessional Education Models- An Evaluative Comparison for the Future of Pharmacy Practice in California, CAPSLEAD, AACP Meeting 7/2015, Harbor MD. (Poster)

## **Invited Seminars:**

- 1. June 2006; Anti-CD22 peptide mimetics bind to CD22, Research Department, Mather VA Hospital, Rancho Cordova, Ca.
- **2.** August 2008; Anti-CD22 Monoclonal Antibodies for the Treatment of Lymphoma, Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Tx
- **3.** August 2008; Anti-CD22 Monoclonal Antibodies for the Treatment of Lymphoma, Clinical Investigation Facility, David Grant Medical Center Travis AFB, Fairfield, Ca.
- **4.** January, 2010; Anti-CD22 peptide mimetics as potential treatment for B-cell lymphoma, Department of Pharmaceutical and Biomedical Sciences, California Northstate College of Pharmacy, Rancho Cordova, Ca.
- **5.** May, 2013; The Ins and Outs of Team-Based Learning (TBL) pedagogy in teaching cellular and molecular biology /biochemistry in a doctor of Pharmacy program. (**90 minute workshop**) 4<sup>th</sup> International ABCD Conference, Santa Fe,Nm.
- **6.** Leanne Coyne, Parto Khansari, Karen McClendon, <u>David Pearson</u>, Tiffanie Ho (2014) AACP Excellence in Assessment Award, AACP Annual Meeting, *Pharmacy Education 2014* in Grapevine, Tx.

## Grants: Completed

American Cancer Society, Florida Chapter

Mechanism of control of bFGF expression by a naturally occurring antisense RNA. Principal Investigator 1 year grant; February 1, 1995 - January 31, 1996 (total \$20,000)

Hibbard Williams Award (UCD Med Center)

Dr. Pearson Co-Investigator, Dr. Pevec the PI: Revascularization of an ishemic limb with a muscle flap: the influence of angiogenic growth factors. July 1, 1997- June 30, 1998 (total \$28,500)

#### Pacific Vascular Research Foundation

Dr. Pearson Co-Investigator, Dr. Pevec the PI: Effects of Brachytherapy on Intimal Hyperplasia in Arteriovenous Fistula in Pigs. September 1, 1997 - August 31, 1998 (Total \$24,124)

### Pacific Vascular Research Foundation renewal

Dr. Pearson Co-Investigator, Dr. Pevec the PI: Effects of Brachytherapy on Intimal Hyperplasia in Arteriovenous Fistula in Pigs. September 1, 1998 - August 31, 1999 (Total \$25,000)

#### Pacific Vascular Foundation

Dr. Pearson Co-investigator, Dr. Pevec the PI: Enhanced Angiogenesis Of An Ischemic Limb With Basic Fibroblast Growth Factor; "Is Muscle Function Improved" March 1, 99 - February 28, 2000 (\$24,259)

#### CNCP Start-up Research Grant.

Dr. Pearson PI. The Development of Novel Peptide Mimetics for the Treatment of Cancer. 2010-2011 (\$20,000)

American Association of Colleges of Pharmacy Research Fellows Program (AACP ARFP). 1 year program \$11,000 for Travel. 7/2013- 7/2014

# **Grants Pending:**

Currently none.

### **Grants:** Not Funded

Shriner's Hospital Research Award

Principal Investigator; Modulation of the immune system in a rat burn model.

3 year grant, total of \$700,000 projected dates 1999-2002

NOTE: Excellent fundable score, yet no <u>new</u> grants were to be initiated at the Sacramento Unit. It was therefore not funded.

VA Merit Grant:

Principal Investigator: CD22-binding Peptides Derived from Highly Conserved Anti-CD22 Ligand Blocking Antibodies Targeted Lymphoma

Year grant total of \$450,000 Projected dates 2005-2008

CNUCOP Post-doc fellowship: Medicinal Plants as a Source for Drug Discovery of Anti-Cancer Activity. \$125,000 Projected date 2013

CNUCOP Seed Grant. The Role of Aberrant CD22 Expression in Non-Hematological Tumors, Dr. Pearson PI. \$9,500

AACP Young Investigator Grant. Evaluation of Selected Plants for Anti lymphoblastic Activity, Dr. Pearson PI. \$10,000

# **Community Service**;

Woodland Community Soccer Coach, 1997

Woodland Community T-ball Coach, 1998, 2004

Science, Engineer design builder for computer club/ Garden advisor for Woodland Christian High and Middle School 2005-2009

Team member "walk for Cancer" Woodland Ca. 2009-2014

Help teaching in Educational Diabetic Clinic 2011-2014

Sacramento Regional Science and Engineering Fair Judge 3/2012

Lee Middle School Career Day 2013, 2014

Douglas Middle School Career Day 2014